Adenoviral-mediated inhibition of connective tissue growth factor in Rat-2 cells

Jennifer L Winkler1, Mamdouh H Kedees, Gladys Teitelman

  • 1Department of Anatomy and Cell Biology, State University of New York (SUNY) Downstate Medical Center, Room 2-94, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.

Insights

A novel viral vector effectively reduced connective tissue growth factor (CTGF) expression in lab studies. This suggests potential for treating diabetic retinopathy (DR) by controlling CTGF levels.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Genetics

Background:

  • Connective tissue growth factor (CTGF) promotes fibrosis and angiogenesis, key factors in diabetic retinopathy (DR) development.
  • Elevated CTGF levels are implicated in the pathogenesis of DR.

Purpose of the Study:

  • To investigate the therapeutic potential of a recombinant adenovirus carrying a CTGF antisense oligonucleotide (rAdASO).
  • To assess the ability of rAdASO to inhibit transforming growth factor-beta (TGF-beta)-induced CTGF expression in fibroblasts.

Main Methods:

  • Utilized semi-quantitative RT-PCR to measure CTGF messenger RNA (mRNA) levels.
  • Employed Western blot and immunocytochemistry to quantify CTGF protein expression.
  • Infected Rat-2 fibroblasts with rAdASO to evaluate its inhibitory effect on TGF-beta-induced CTGF.

Main Results:

  • TGF-beta significantly increased CTGF mRNA and protein levels (2-fold increase in mRNA).
  • Infection with rAdASO effectively inhibited the TGF-beta-induced upregulation of CTGF.
  • Demonstrated successful reduction of CTGF expression by the rAdASO viral vector in vitro.

Conclusions:

  • The rAdASO viral vector demonstrates efficacy in decreasing TGF-beta-induced CTGF expression in fibroblasts.
  • This approach holds therapeutic promise for managing elevated CTGF levels in diabetic retinopathy.
  • Further research may validate rAdASO as a treatment strategy for DR.